137 related articles for article (PubMed ID: 28284458)
1. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell.
Tessoulin B; Eveillard M; Lok A; Chiron D; Moreau P; Amiot M; Moreau-Aubry A; Le Gouill S; Pellat-Deceunynck C
Blood Rev; 2017 Jul; 31(4):251-259. PubMed ID: 28284458
[TBL] [Abstract][Full Text] [Related]
2. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
3. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
4. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma.
Davies AJ; Lee AM; Taylor C; Clear AJ; Goff LK; Iqbal S; Cuthbert-Heavens D; Calaminici M; Norton AJ; Lister TA; Fitzgibbon J
Leukemia; 2005 Aug; 19(8):1459-65. PubMed ID: 15902285
[TBL] [Abstract][Full Text] [Related]
5. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
6. MYC rearranged B-cell neoplasms: Impact of genetics on classification.
Haberl S; Haferlach T; Stengel A; Jeromin S; Kern W; Haferlach C
Cancer Genet; 2016 Oct; 209(10):431-439. PubMed ID: 27810071
[TBL] [Abstract][Full Text] [Related]
7. Loss of p73 promotes dissemination of Myc-induced B cell lymphomas in mice.
Nemajerova A; Petrenko O; Trümper L; Palacios G; Moll UM
J Clin Invest; 2010 Jun; 120(6):2070-80. PubMed ID: 20484818
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.
Zainuddin N; Berglund M; Wanders A; Ren ZP; Amini RM; Lindell M; Kanduri M; Roos G; Rosenquist R; Enblad G
Leuk Res; 2009 Jan; 33(1):60-6. PubMed ID: 18706692
[TBL] [Abstract][Full Text] [Related]
9. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-124 links p53 to the NF-κB pathway in B-cell lymphomas.
Jeong D; Kim J; Nam J; Sun H; Lee YH; Lee TJ; Aguiar RC; Kim SW
Leukemia; 2015 Sep; 29(9):1868-74. PubMed ID: 25915824
[TBL] [Abstract][Full Text] [Related]
11. Tp53 deletion in B lineage cells predisposes mice to lymphomas with oncogenic translocations.
Rowh MA; DeMicco A; Horowitz JE; Yin B; Yang-Iott KS; Fusello AM; Hobeika E; Reth M; Bassing CH
Oncogene; 2011 Nov; 30(47):4757-64. PubMed ID: 21625223
[TBL] [Abstract][Full Text] [Related]
12. Inactivation of p53 is insufficient to allow B cells and B-cell lymphomas to survive without Dicer.
Adams CM; Eischen CM
Cancer Res; 2014 Jul; 74(14):3923-34. PubMed ID: 24840646
[TBL] [Abstract][Full Text] [Related]
13. Targeting CK2-driven non-oncogene addiction in B-cell tumors.
Mandato E; Manni S; Zaffino F; Semenzato G; Piazza F
Oncogene; 2016 Nov; 35(47):6045-6052. PubMed ID: 27041560
[TBL] [Abstract][Full Text] [Related]
14. The significance of TP53 in lymphoid malignancies: mutation prevalence, regulation, prognostic impact and potential as a therapeutic target.
Cheung KJ; Horsman DE; Gascoyne RD
Br J Haematol; 2009 Aug; 146(3):257-69. PubMed ID: 19500100
[TBL] [Abstract][Full Text] [Related]
15. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
16. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
17. Rational combination therapies targeting survival signaling in aggressive B-cell leukemia/lymphoma.
Waibel M; Gregory G; Shortt J; Johnstone RW
Curr Opin Hematol; 2014 Jul; 21(4):297-308. PubMed ID: 24811162
[TBL] [Abstract][Full Text] [Related]
18. Complex analysis of the TP53 tumor suppressor in mantle cell and diffuse large B-cell lymphomas.
Zlamalikova L; Moulis M; Ravcukova B; Liskova K; Malcikova J; Salek D; Jarkovsky J; Svitakova M; Hrabalkova R; Smarda J; Smardova J
Oncol Rep; 2017 Oct; 38(4):2535-2542. PubMed ID: 28791403
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of the ARF-MDM-2-p53 pathway in sporadic Burkitt's lymphoma in children.
Wilda M; Bruch J; Harder L; Rawer D; Reiter A; Borkhardt A; Woessmann W
Leukemia; 2004 Mar; 18(3):584-8. PubMed ID: 14712292
[TBL] [Abstract][Full Text] [Related]
20. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
Meng X; Carlson NR; Dong J; Zhang Y
Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
